Flory T Muanda1,2, Matthew A Weir3,2,4, Lavanya Bathini3,4, Kristin K Clemens3,5, Vlado Perkovic6, Manish M Sood3,7, Eric McArthur3, Jessica M Sontrop4, Richard B Kim8, Amit X Garg3,2,4. 1. ICES, Kidney, Dialysis and Transplantation Research Program, Ontario, Canada Flory.Muanda-Tsobo@lhsc.on.ca. 2. Department of Epidemiology and Biostatistics, Western University, London, Canada. 3. ICES, Kidney, Dialysis and Transplantation Research Program, Ontario, Canada. 4. Division of Nephrology, Department of Medicine, Western University, London, Canada. 5. Division of Endocrinology and Metabolism, Department of Medicine, Western University, London, Canada. 6. The George Institute for Global Health, University of New South Wales, Sydney, Australia. 7. The Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada. 8. Division of Clinical Pharmacology, Department of Medicine, Western University, London, Ontario, Canada.
Abstract
BACKGROUND AND OBJECTIVES: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a higher risk of congestive heart failure, particularly at higher doses. We compare the 1-year risk of death or hospitalization with congestive heart failure in patients with CKD newly prescribed sitagliptin at >50 versus ≤50 mg/d. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This population-based cohort study included older adults (>66 years) with type 2 diabetes and an eGFR<45 ml/min per 1.73 m2 (but not receiving dialysis) who were newly prescribed sitagliptin between 2010 and 2017 in Ontario, Canada. We used inverse probability of treatment weighting on the basis of propensity scores to balance baseline characteristics. The primary composite outcome was death or hospitalization with congestive heart failure. Secondary outcomes included hospitalization with pancreatitis or hypoglycemia, all-cause hospitalization, and glycemic control. Weighted hazard ratios were obtained using Cox proportional hazards regression, and 95% confidence intervals were obtained using bootstrap variance estimators. RESULTS: Of 9215 patients, 6518 started sitagliptin at >50 mg/d, and 2697 started sitagliptin at ≤50 mg/d. The 1-year risk of death or hospitalization with congestive heart failure did not differ significantly between groups (79 versus 126 events per 1000 person-years; weighted hazard ratio, 0.88; 95% confidence interval, 0.67 to 1.14); hospitalization with pancreatitis (weighted hazard ratio, 0.98; 95% confidence interval, 0.32 to 3.03) and hypoglycemia (weighted hazard ratio, 1.10; 95% confidence interval, 0.64 to 1.90) also did not differ significantly between groups. Patients starting sitagliptin at >50 mg/d had lower mean glycated hemoglobin concentrations (weighted between-group difference, -0.12%; 95% confidence interval, -0.19 to -0.06) and a lower risk of all-cause hospitalization (weighted hazard ratio, 0.81; 95% confidence interval, 0.66 to 0.98). CONCLUSIONS: The risk of death or congestive heart failure was not higher in older adults with CKD starting sitagliptin at >50 versus ≤50 mg/d. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_11_25_CJN08310520_final.mp3.
BACKGROUND AND OBJECTIVES: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a higher risk of congestive heart failure, particularly at higher doses. We compare the 1-year risk of death or hospitalization with congestive heart failure in patients with CKD newly prescribed sitagliptin at >50 versus ≤50 mg/d. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This population-based cohort study included older adults (>66 years) with type 2 diabetes and an eGFR<45 ml/min per 1.73 m2 (but not receiving dialysis) who were newly prescribed sitagliptin between 2010 and 2017 in Ontario, Canada. We used inverse probability of treatment weighting on the basis of propensity scores to balance baseline characteristics. The primary composite outcome was death or hospitalization with congestive heart failure. Secondary outcomes included hospitalization with pancreatitis or hypoglycemia, all-cause hospitalization, and glycemic control. Weighted hazard ratios were obtained using Cox proportional hazards regression, and 95% confidence intervals were obtained using bootstrap variance estimators. RESULTS: Of 9215 patients, 6518 started sitagliptin at >50 mg/d, and 2697 started sitagliptin at ≤50 mg/d. The 1-year risk of death or hospitalization with congestive heart failure did not differ significantly between groups (79 versus 126 events per 1000 person-years; weighted hazard ratio, 0.88; 95% confidence interval, 0.67 to 1.14); hospitalization with pancreatitis (weighted hazard ratio, 0.98; 95% confidence interval, 0.32 to 3.03) and hypoglycemia (weighted hazard ratio, 1.10; 95% confidence interval, 0.64 to 1.90) also did not differ significantly between groups. Patients starting sitagliptin at >50 mg/d had lower mean glycated hemoglobin concentrations (weighted between-group difference, -0.12%; 95% confidence interval, -0.19 to -0.06) and a lower risk of all-cause hospitalization (weighted hazard ratio, 0.81; 95% confidence interval, 0.66 to 0.98). CONCLUSIONS: The risk of death or congestive heart failure was not higher in older adults with CKD starting sitagliptin at >50 versus ≤50 mg/d. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_11_25_CJN08310520_final.mp3.
Authors: Subodh Verma; Ronald M Goldenberg; Deepak L Bhatt; Michael E Farkouh; Adrian Quan; Hwee Teoh; Kim A Connelly; Lawrence A Leiter; Jan O Friedrich Journal: CMAJ Open Date: 2017-02-24
Authors: Faiez Zannad; Christopher P Cannon; William C Cushman; George L Bakris; Venu Menon; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; Hung Lam; William B White Journal: Lancet Date: 2015-03-10 Impact factor: 79.321
Authors: Samuel S Engel; Shailaja Suryawanshi; Susanna R Stevens; Robert G Josse; Jan H Cornel; Neli Jakuboniene; Axel Riefflin; Tsvetalina Tankova; Julio Wainstein; Eric D Peterson; Rury R Holman Journal: Diabetes Obes Metab Date: 2017-07-07 Impact factor: 6.577
Authors: Sonja Gandhi; Jamie L Fleet; David G Bailey; Eric McArthur; Ron Wald; Faisal Rehman; Amit X Garg Journal: JAMA Date: 2013-12-18 Impact factor: 56.272
Authors: Kristin K Clemens; Salimah Shariff; Kuan Liu; Irene Hramiak; Jeffrey L Mahon; Eric McArthur; Amit X Garg Journal: PLoS One Date: 2015-09-03 Impact factor: 3.240